跳至主要内容
临床试验/NCT00697814
NCT00697814已完成2 期

Recovery of Gonadal Function by Clomiphene in Males With Prolactinomas and Persistent Hypogonadism

Federal University of São Paulo1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2004年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
15
试验地点
1
主要终点
assess the effects of CC treatment on testosterone levels in male patients with prolactinomas and persistent HH on dopaminergic agonist therapy

研究概览

简要总结

Prolactinomas are usually associated with hypogonadotropic hypogonadism in both sexes. Clomiphene citrate is a well known selective estrogen receptor modulator that increases gonadotropin secretion via hypothalamic-pituitary action. We conducted a prospective, open label clinical trial of CC to evaluate its effects in reverting persistent HH in male patients with prolactinomas under dopaminergic agonist treatment.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • a minimum follow-up of 6 months under DA therapy with normal serum prolactin or with maximum DA dose (3.5 mg/week of cabergoline or 10 mg/day of bromocriptine for at least 2 months)
  • serum total testosterone less than 300ng/dl with normal or low LH and FSH levels after discontinuing testosterone replacement for at least 2 months.

排除标准

  • impossibility to attend scheduled visits and irregular compliance to DA treatment.

研究组 & 干预措施

Clomiphene

Experimental

Clomiphene 50 mg/day for 12 weeks

干预措施: Clomiphene citrate (Drug)

结局指标

主要结局

assess the effects of CC treatment on testosterone levels in male patients with prolactinomas and persistent HH on dopaminergic agonist therapy

时间窗: 10 days, 4, 8 and 12 weeks

次要结局

  • Assess the effects of CC on sexual function, fertility, body composition, lipid and glucose metabolism, and quality of life were also evaluated.

研究者

发起方
Federal University of São Paulo
申办方类型
Other

研究点 (1)

Loading locations...

相似试验